Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million Series B financing to ...
Epilepsy Patient Samples Offer Unprecedented Insights on Brain 'Brakes' Linked to Disorders Jan. 23, 2025 — Specific protein receptors in the brain play a vital role in how neurons slow down or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback